<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03221426</url>
  </required_header>
  <id_info>
    <org_study_id>3475-585</org_study_id>
    <secondary_id>2016-004408-76</secondary_id>
    <secondary_id>MK-3475-585</secondary_id>
    <secondary_id>173786</secondary_id>
    <nct_id>NCT03221426</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the
      neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated
      adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

      The primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to
      placebo plus chemotherapy in terms of overall survival (OS), event-free survival (EFS) and
      pathological complete response (pathCR) rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2017</start_date>
  <completion_date type="Anticipated">July 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 26, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>EFS is defined as the time from randomization to the first of the following events: radiographic disease progression per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1); local or distant recurrence as assessed by computer tomography (CT) scan or biopsy if indicated (for participants who are disease free after surgery); or death due to any cause. A second primary malignancy is not considered as an EFS event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological Complete Response (pathCR) Rate</measure>
    <time_frame>Up to 6 weeks after completion of 3 cycles of neoadjuvant treatment (Up to 15 weeks)</time_frame>
    <description>PathCR rate is defined as the percentage of participants having pathCR. pathCR is defined as no invasive disease within an entirely submitted and evaluated gross lesion, and histologically negative nodes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 27 months</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study Treatment Discontinuations Due to AEs</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>DFS is defined as the time from post-surgery baseline scan until the first occurrence of local/distant recurrence or death from any cause and is based on RECIST 1.1 as assessed by blinded independent central review.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) via continuous IV infusion on Days 1 to 5 of each 3-week cycle.
Adjuvant: 4 to 10 weeks post-surgery, participants receive pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 14 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle.
Adjuvant: 4 to 10 weeks post-surgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 14 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+FLOT Safety Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.
Adjuvant: 4 to 10 weeks postsurgery, participants receive pembrolizumab 200 mg via IV infusion Day 1 Q3W for up to 11 cycles PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+FLOT Safety Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.
Adjuvant: 4 to 10 weeks postsurgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Chemotherapy</arm_group_label>
    <arm_group_label>Pembrolizumab+FLOT Safety Cohort</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution IV infusion</description>
    <arm_group_label>Placebo+Chemotherapy</arm_group_label>
    <arm_group_label>Placebo+FLOT Safety Cohort</arm_group_label>
    <other_name>Normal saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Chemotherapy</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy</arm_group_label>
    <other_name>PLATINOL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Pembrolizumab+Chemotherapy</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy</arm_group_label>
    <other_name>XELODA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+Chemotherapy</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy</arm_group_label>
    <arm_group_label>Pembrolizumab+FLOT Safety Cohort</arm_group_label>
    <arm_group_label>Placebo+FLOT Safety Cohort</arm_group_label>
    <other_name>ADRUCIL®</other_name>
    <other_name>5FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FLOT Safety Cohort</arm_group_label>
    <arm_group_label>Placebo+FLOT Safety Cohort</arm_group_label>
    <other_name>TAXOTERE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FLOT Safety Cohort</arm_group_label>
    <arm_group_label>Placebo+FLOT Safety Cohort</arm_group_label>
    <other_name>ELOXATIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FLOT Safety Cohort</arm_group_label>
    <arm_group_label>Placebo+FLOT Safety Cohort</arm_group_label>
    <other_name>WELLCOVORIN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has previously untreated localized gastric or GEJ adenocarcinoma as defined by T3 or
             greater primary lesion or the presence of any positive nodes - N+ (clinical nodes)
             without evidence of metastatic disease.

          -  Plans to proceed to surgery following pre-operative chemotherapy based on standard
             staging studies per local practice.

          -  Is willing to provide tissue from a tumor lesion at baseline and at time of surgery.

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1
             within 3 days prior to the first dose of study treatment.

          -  Has adequate organ function.

          -  Male participants of childbearing potential must agree to use an adequate method of
             contraception for the course of the study through 180 days after the last dose of
             chemotherapy.

          -  Female participants of childbearing potential must be willing to use an adequate
             method of contraception for the course of the study through 180 days after the last
             dose of chemotherapy or through 120 days after the last dose of pembrolizumab,
             whichever is greater.

          -  Has life expectancy of greater than 6 months.

        Exclusion Criteria:

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Is currently participating in or has participated in a trial of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment.

          -  Has received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1),
             anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent
             directed to another stimulatory or co-inhibitory T-cell receptor (i.e., cytotoxic
             T-lymphocyte-associated protein 4 [CTLA-4], tumor necrosis factor receptor superfamily
             member 4 [OX-40], necrosis factor receptor superfamily member 9 [CD137]) or has
             previously participated in a Merck pembrolizumab (MK-3475) clinical trial.

          -  Has received prior systemic anti-cancer therapy including investigational agents for
             the current malignancy.

          -  Has received prior radiotherapy within 2 weeks of start of study treatment for any
             other condition.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 14 days prior the first dose of study treatment.

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 5 years. Note: Participants with basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, or carcinoma in situ that have undergone
             potentially curative therapy are not excluded.

          -  Has a known severe hypersensitivity (≥ Grade 3) to pembrolizumab, its active substance
             and/or any of its excipients, or to any of the study chemotherapy agents and/or to any
             of their excipients.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection.

          -  Has a known history of active tuberculosis (TB).

          -  Female participants who are pregnant or breastfeeding or expecting to conceive
             children within the projected duration of the study, starting with the screening visit
             through180 days after the last dose of chemotherapy or through 120 days after the last
             dose of pembrolizumab, whichever is greater.

          -  Male participants who are expecting to father children within the projected duration
             of the study, starting with the screening visit through 180 days after the last dose
             of chemotherapy.

          -  Has received a live vaccine within 30 days prior to the first dose of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope ( Site 0005)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>626-471-9200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center ( Site 0016)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-785-6661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University ( Site 0015)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-585-0330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center ( Site 0004)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-702-7596</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute ( Site 0001)</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>877-275-7724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0019)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-1781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center ( Site 0006)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-214-4283</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital ( Site 0026)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-214-4283</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah, Huntsman Cancer Institute ( Site 0012)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>585-275-5823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC ( Site 0010)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>703-280-5390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme ULB ( Site 0484)</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3225553714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Saint Luc ( Site 0479)</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3227641274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi ( Site 0478)</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3271104730</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge ( Site 0481)</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3256633338</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven ( Site 0483)</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3216344218</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Sart Tilman ( Site 0482)</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3243667256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional Do Cancer Jose Alencar Gomes Da Silva ( Site 0307)</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+552132076564</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer de Sao Paulo - ICESP ( Site 0305)</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551138932615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0304)</name>
      <address>
        <city>Sao José do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551732015054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital ( Site 0034)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5143408222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0035)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>819346111016216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Rancagua Libertador Bernardo O Higgins ( Site 0299)</name>
      <address>
        <city>Rancagua</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998 9000000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez FALP ( Site 0286)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56224457254</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universidad de Chile ( Site 0287)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998865341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile ( Site 0285)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56222472327</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico del Sur. ICOS ( Site 0290)</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56994443272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest - Institut de Cancerologie et d Hematologie ( Site 0474)</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33298223428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Jean Mermoz ( Site 0462)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33437538764</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine ( Site 0471)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33171970401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris ( Site 0463)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33156616241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis ( Site 0466)</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33299253159</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0469)</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33240679900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus der TU Dresden ( Site 0448)</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493514584794</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte Gmbh Evang. Huyssens Stiftung ( Site 0445)</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4920117424524</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen GmbH ( Site 0453)</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4971131032451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg ( Site 0450)</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4976127028080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische klinilk und Poliklinik Johannes Gutenberg Univ ( Site 0455)</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496131176076</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka University M.C ( Site 0385)</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972864000798</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus ( Site 0381)</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247776731</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center ( Site 0383)</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226777957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir medical center ( Site 0386)</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297472393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin-Medical Center ( Site 0384)</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378081</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center. ( Site 0382)</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas Research Hospital ( Site 0432)</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390282244080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0429)</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+300594224383</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0430)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223903835</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Veneto ( Site 0431)</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390498215910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato ( Site 0433)</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3902527741</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Santa Maria della Misericordia di Udine ( Site 0434)</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390432559330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital ( Site 0165)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81527626111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 0178)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81471331111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center ( Site 0186)</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81899991111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital ( Site 0160)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81117161161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center ( Site 0182)</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81789291151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital ( Site 0181)</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81783024321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital ( Site 0188)</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81783825111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital ( Site 0177)</name>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81296771121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital ( Site 0184)</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81196515111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center ( Site 0167)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81455202222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital ( Site 0162)</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81668795111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital ( Site 0168)</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81726831221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center ( Site 0170)</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81487221111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center Hospital and Research Institute ( Site 0176)</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81559895222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center ( Site 0180)</name>
      <address>
        <city>Chiba</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81432645431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital ( Site 0173)</name>
      <address>
        <city>Fukuoka</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81926411151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center ( Site 0172)</name>
      <address>
        <city>Fukuoka</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81925413231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital ( Site 0166)</name>
      <address>
        <city>Gifu</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81582306000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital ( Site 0171)</name>
      <address>
        <city>Hiroshima</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81822212291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kochi Health Sciences Center ( Site 0189)</name>
      <address>
        <city>Kochi</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81888373000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital ( Site 0164)</name>
      <address>
        <city>Kumamoto</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81963442111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital ( Site 0169)</name>
      <address>
        <city>Niigata</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81252665111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center ( Site 0159)</name>
      <address>
        <city>Osaka</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81666921201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 0161)</name>
      <address>
        <city>Osaka</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669451181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 0179)</name>
      <address>
        <city>Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335422511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 0185)</name>
      <address>
        <city>Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335200111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Komagome Hospital ( Site 0183)</name>
      <address>
        <city>Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81338232101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyama Prefectural Central Hospital ( Site 0163)</name>
      <address>
        <city>Toyama</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81764241531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 0085)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877037</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital ( Site 0083)</name>
      <address>
        <city>Hwasun Gun</city>
        <state>Jeollanam Do</state>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82613797623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 0082)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital -SNUH- ( Site 0080)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82220722236</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0081)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288132</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMG-SNU BORAMAE Medical Center ( Site 0086)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8228702231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 0084)</name>
      <address>
        <city>Seou</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8229206082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 0353)</name>
      <address>
        <city>Koscierzyna</city>
        <state>Pomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48793929449</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 0354)</name>
      <address>
        <city>Bielsko-Biala</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48334984045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie ( Site 0352)</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48124248912</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 0351)</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48815344313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPZOZ WSS nr 3 w Rybniku ( Site 0357)</name>
      <address>
        <city>Rybnik</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48603759221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny we Wroclawiu ( Site 0358)</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48606753363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical and Surgical Center n.a. N.I.Pirogov ( Site 0338)</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74956037218</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0344)</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219462123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Oncology Cent ( Site 0335)</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219650996</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City clinical oncological dispensary ( Site 0336)</name>
      <address>
        <city>Sankt-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78127569923</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tomsk Scientific Research Institute of Oncology ( Site 0337)</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73822418091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore ( Site 0097)</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6564368497</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital ( Site 0095)</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6567724670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncocare Cancer Centre ( Site 0096)</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6567723905</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 0067)</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center ( Site 0066)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886228970011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital ( Site 0065)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886225433535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 0063)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886223123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation. Linkou Branch ( Site 0064)</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88633281200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust ( Site 0400)</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442089156196</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust ( Site 0402)</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442033113311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust ( Site 0403)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+44207794050032325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Foundation Trust ( Site 0405)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442089156196</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust ( Site 0397)</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441614468342</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Colombia</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

